论文部分内容阅读
目的:探讨罗格列酮减少糖尿病肾病患者蛋白尿的疗效。方法:120例糖尿病肾病患者按蛋白尿定性分为轻度(±～+)32例、中度(++)48例、重度(+++～++++)40例共3组,每组又平均分为观察组和对照组,分别予ACEI/ARB及ACEI/ARB联合罗格列酮治疗,疗程6个月,观察两组蛋白尿减少程度及减少时间。结果:观察组患者尿蛋白下降程度较对照组患者显著(P<0.05或P<0.01),而且尿蛋白下降人数达观察人数的半数所需时间均明显短于对照组(P<0.01)。结论:罗格列酮能显著降低糖尿病肾病患者蛋白尿程度,并能减少蛋白尿转阴时间。
Objective: To investigate the effect of rosiglitazone in reducing proteinuria in patients with diabetic nephropathy. Methods: 120 patients with diabetic nephropathy were divided into three groups: mild (+ ~ +), moderate (++) 48, moderate (+++ ~ +++) 40, Groups were equally divided into observation group and control group, respectively, ACEI / ARB and ACEI / ARB combined with rosiglitazone treatment, the course of 6 months, observed the degree of albuminuria in both groups and reduce the time. Results: The decrease of urinary protein in the observation group was more significant than that in the control group (P <0.05 or P <0.01), and the time required for the decrease of urinary protein in half of the observation group was significantly shorter than that in the control group (P <0.01). Conclusion: Rosiglitazone can significantly reduce the degree of proteinuria in patients with diabetic nephropathy, and can reduce the proteinuria negative time.